EDP-323正在进行1期双盲、安慰剂对照研究,旨在评...查看全文
SeekingBiotech2023-04-09 21:23
$Enanta制药(ENTA)$
ENTA Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus查看全文
药时代03-22 18:58
回首往昔,2023年算是NASH(后更名为MASH)治疗领域黎明前夕的最后一抹暗夜。
这一年,Intercept做出了最终决定,宣告终止奥贝胆酸用于NASH领域的开发。历经十数载的坎坷探索,奥贝胆酸在NASH战场上几经挫折、屡败屡战的研发历程至此画上了句号。
令人唏嘘的结果背后,映射的是业界对MASH...查看全文
Enanta(ENTA)03-09 06:35
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006052 Size: 5 KB 网页链接查看全文
Enanta(ENTA)03-13 04:05
$Enanta制药(ENTA)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0000950170-24-029889 Act: 34 Size: 349 KB 网页链接查看全文
Enanta(ENTA)03-09 06:15
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006036 Size: 5 KB 网页链接查看全文
Enanta(ENTA)03-09 06:25
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006046 Size: 5 KB 网页链接查看全文
Enanta(ENTA)03-09 06:25
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006038 Size: 5 KB 网页链接查看全文
Enanta(ENTA)03-09 06:25
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006042 Size: 5 KB 网页链接查看全文
智通财经APP获悉,美国生物技术公司Enanta Pharmaceuticals(ENTA.US)表示,其潜在的治疗COVID-19的口服药物EDP-235在临床前研究中显示出抗病毒活性。 该公司表示,在一项生化分析中,EDP-235抑制了SARS-CoV-2 3CLpro蛋白酶,这种活性在S... 网页链接
$Enanta制药(ENTA)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0000950170-24-029889 Act: 34 Size: 349 KB 网页链接
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006050 Size: 5 KB 网页链接
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006052 Size: 5 KB 网页链接
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006038 Size: 5 KB 网页链接
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006042 Size: 5 KB 网页链接
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006046 Size: 5 KB 网页链接
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006036 Size: 5 KB 网页链接
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-004659 Size: 7 KB 网页链接
$Enanta制药(ENTA)$ SCHEDULE 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001609251-24-000004 Act: 34 Size: 33 KB 网页链接
$Enanta制药(ENTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-003233 Size: 7 KB 网页链接